Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. - Wikidata - wikimedia - TriplyDB

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

http://www.wikidata.org/entity/Q46232500

about

Recent advances of novel targeted therapy in non-small cell lung cancer Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer Translatability scoring in drug development: eight case studies Third-line systemic treatment for non-small cell lung cancer Clinical use of crizotinib for the treatment of non-small cell lung cancer Optimizing the management of advanced non-small-cell lung cancer: a personal view Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer Second-Line Therapy for Advanced NSCLC Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review Targeted therapies in development for non-small cell lung cancer Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review Advances of molecular subtype and targeted therapy of lung cancer Molecular pathology of lung cancer: key to personalized medicine.EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)Promising targets and current clinical trials in metastatic squamous cell lung cancer Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor Novel insights into the molecular origins and treatment of lung cancer EGFR-TKI resistance in NSCLC patients: mechanisms and strategies Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

P2860

Q21092930-C7DBDC22-C76A-46FA-ABF5-0E613E66BA34 Q21132047-484F7818-98B1-4C87-892F-922531DE7E52 Q22241671-F14AC178-143B-4BC8-B13B-099C68BDE15A Q22241760-E2D5424E-7290-4184-A668-3EEEFFF86A5D Q24194090-392741F4-93D9-4BCA-B4DA-FAB79ABADC88 Q24630466-A9F0AD07-4389-4EFA-B159-D962AD34DA96 Q24656144-18D95314-0A7A-48E4-A58F-3E189551C584 Q26750428-FDDF3529-C691-4070-B0DA-74167D9B51A9 Q26767182-043D7BE4-6DC9-45A9-9C33-0B484E0D0537 Q26768125-49DC4896-34D4-4FFB-9736-76EF6564675D Q26775603-324881FE-405D-4E28-B39D-06D36D229E46 Q26775677-6F61A18F-CF43-4C3A-BA02-D45518A41A68 Q26781810-B440B10F-283C-4BE9-90B0-9F9D75A532CB Q26798882-99B1041B-9566-412C-9072-1DEA99114780 Q26799467-F5779475-183C-4388-AE1B-3E3B8940C5D5 Q26800148-1D07876F-A7B6-407D-9CFC-B64085B970DB Q26827571-68CDA6BC-9190-4346-BDC4-F71E472797FF Q26829425-CEFCC531-070D-4892-B848-6600A3280C96 Q26829939-6D774FE9-04DD-4372-A089-3830F04C050D Q26852202-599A097F-11FD-440A-A0E7-B37BDB3278BC Q26852507-AF0B9B4F-BE17-41F5-A7C6-7896AF60CA6D Q27002398-F16A6678-5379-4A31-A3CD-04AEB260D5ED Q27003440-34AB5294-0A86-4D6F-800B-A36F2C2FADD5 Q27021738-24606AB8-89BA-4798-8152-2842E4F4AA8E Q27022535-5EC981F2-1A6F-43AA-8B62-FCE9B4C1B2EC Q27022852-A7DCDF6A-4422-450B-9B5C-28A370538F7B Q27025724-19820A56-2F74-42ED-AA98-C0365139C10C Q27030813-BE1FFFC4-AFB8-4383-A64F-A9787B579D9D Q27691299-BCD328F2-31C9-43D1-AD8B-E2F987085A7E Q27851583-E6D7B822-AA2F-4BA9-B254-035F4FE62FBD Q27851729-B189550A-A3C4-45F2-9A0B-619CC965BCC3 Q27851872-E5B15E02-8A03-4B53-98FA-62A787FB427E Q28073920-3306EFFB-1766-4225-B442-4B471AA9E362 Q28083663-B00D0002-C796-4E7F-A3FC-F2101C82B377 Q28284519-43EB00FC-6565-4423-922E-AD000DACAB8E Q28382921-ECC296EF-41CA-405E-8814-6F6CC6CADAED Q28386773-40D6B449-7A1E-49C2-9C56-70A459A3EA40 Q28394310-FA148C11-1B3B-4AF7-9F2A-0C58D0CA1DB2 Q28830889-D6968758-BAFD-454A-958E-490363B74B97 Q29620902-C7931B65-28EA-4791-8E2E-897F497377BE

P2860

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

http://www.wikidata.org/entity/Q46232500

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Gefitinib versus docetaxel in ...... a randomised phase III trial.

@en

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer

@nl

type

label

Gefitinib versus docetaxel in ...... a randomised phase III trial.

@en

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer

@nl

prefLabel

Gefitinib versus docetaxel in ...... a randomised phase III trial.

@en

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer

@nl

P1433

Q46232500-567AD01E-195F-4048-ADB2-7586400AD034

P1476

Q46232500-D30FE334-0744-4576-A2C6-120A0DD4D8A2

P2093

Q46232500-037BFA4E-6D2E-418D-9683-A5C46136CDDE

Q46232500-118E86C3-DCBA-467C-9023-A1455D0F3042

Q46232500-1DC33847-0CC1-473F-B04F-1A3D84C43B05

Q46232500-276B2063-DEB7-4F5F-953D-2F6B9C5B4A8C

Q46232500-292D265F-0BF6-4BB1-98CF-7B80EEE65FFF

Q46232500-3A0E1FDB-813C-4C29-9722-6BBACCE64BF2

Q46232500-45619F0C-1A7D-41D8-A37B-22AEC7AEC0B0

Q46232500-4AD2B1FD-6C62-4B9E-8903-F670F333A29C

Q46232500-5A0B95FF-2BD2-4FBA-9FA5-A00B1CD704DA

Q46232500-9580E689-70B0-492F-9F5C-943A2388E85B

P304

Q46232500-F2E4EC53-E120-4DAE-95D7-32B9EC2048C3

P31

Q46232500-368F65F3-A501-4FD7-8235-2301C0E65415

P356

Q46232500-CD6A7266-DA73-4F7D-977C-121A22AF6967

P407

Q46232500-6BFA7F7C-651B-4906-B0AB-5A23BA39DCCB

P433

Q46232500-19F754B8-D3A3-4EF2-858A-F58FFF3964D0

P478

Q46232500-4202E208-3061-4FA1-9057-719CD04F8AF4

P50

Q46232500-52021DC6-34A1-443C-8C4E-4631DE2BAFF8

Q46232500-6F4936A6-C243-41C2-8B1D-C66825AC3B5B

Q46232500-AD6BECA0-B6EF-46B4-9065-11E3728DDA86

P577

Q46232500-C37FC0A7-2807-471B-90BF-44CD8B1F6A0D

P698

Q46232500-3C3F2D8B-F345-4C82-AC3A-9325F21FAE34

P921

Q46232500-9F808475-D405-4716-9403-594B09F78591

P356

S0140-6736(08)61758-4

P1433

P1476

Gefitinib versus docetaxel in ...... : a randomised phase III trial

@en

P2093

Alison A Armour

http://www.w3.org/2001/XMLSchema#string

Claire L Watkins

http://www.w3.org/2001/XMLSchema#string

Edward S Kim

http://www.w3.org/2001/XMLSchema#string

Elizabeth S Lowe

http://www.w3.org/2001/XMLSchema#string

Frances A Shepherd

http://www.w3.org/2001/XMLSchema#string

Kell Osterlind

http://www.w3.org/2001/XMLSchema#string

Long-Yun Li

http://www.w3.org/2001/XMLSchema#string

Mark A Socinski

http://www.w3.org/2001/XMLSchema#string

Mark V Sellers

http://www.w3.org/2001/XMLSchema#string

Martin Reck

http://www.w3.org/2001/XMLSchema#string

P304

1809-1818

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(08)61758-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

9652

http://www.w3.org/2001/XMLSchema#string

P478

372

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Yves Douillard

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19027483

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial